Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

11.07
-0.4000-3.49%
Post-market: 11.070.00000.00%16:10 EDT
Volume:952.93K
Turnover:10.78M
Market Cap:633.87M
PE:-13.26
High:11.67
Open:11.39
Low:11.03
Close:11.47
52wk High:18.33
52wk Low:1.54
Shares:57.26M
Float Shares:41.29M
Volume Ratio:0.70
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8347
EPS(LYR):-0.8974
ROE:-27.10%
ROA:-18.45%
PB:2.65
PE(LYR):-12.34

Loading ...

Climb Bio Director Thomas Stephen Basil Disposes of $1,366,820 in Common Shares

Reuters
·
Sep 18

Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Climb Bio price target raised to $25 from $18 at Oppenheimer

TIPRANKS
·
Sep 08

Climb Bio is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 08

Climb Bio, Inc. : H.c. Wainwright Raises Target Price to $30 from $24

THOMSON REUTERS
·
Sep 08

Climb Bio Price Target Raised to $30.00/Share from $26.00 by B. Riley Securities

Dow Jones
·
Sep 05

Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says

MT Newswires Live
·
Sep 04

U.S. Research Roundup-Ciena Corp, Docusign, Snowflake

Reuters
·
Sep 04

Climb Bio Inc : Btig Raises Target Price to $32 from $20

THOMSON REUTERS
·
Sep 04

Climb Bio price target raised to $25 from $21 at Baird

TIPRANKS
·
Sep 04

Wedbush Adjusts Price Target on Climb Bio to $25 From $20, Keeps Outperform Rating

MT Newswires Live
·
Sep 03

Climb Bio price target raised to $40 from $23 at Piper Sandler

TIPRANKS
·
Sep 03

U.S. Stocks on the MOVE-Gold Miners, Polestar Automotive, Nvidia

Reuters
·
Sep 03

Climb Bio Reports Early Phase 1 Data for IgA Nephropathy Drug

MT Newswires Live
·
Sep 03

Climb Bio - Announces Positive Phase 1 Data for Clym116 in Iga Nephropathy

THOMSON REUTERS
·
Sep 03

Climb Bio - Phase 2 Navigate-2 Trial Ongoing; Initial Data Expected H1 2027, Phase 3 Initiation in 2027

THOMSON REUTERS
·
Sep 03

Climb Bio - Clym116 Well-Tolerated with no Serious Adverse Events or Dose-Limiting Toxicities

THOMSON REUTERS
·
Sep 03

Climb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says

MT Newswires Live
·
Sep 03

Climb Bio's Upcoming CLYM116 Data Could Support Longer Dosing, Strong Potency, Oppenheimer Says

MT Newswires Live
·
Aug 31

Climb Bio is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 24